Comparison of treatment satisfaction after switching from Semaglutide to Dulaglutide in patients with type 2 diabetes:a pilot study
- Conditions
- Type 2 diabetes
- Registration Number
- JPRN-UMIN000047266
- Lead Sponsor
- Yokosuka Kyosai Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 15
Not provided
(1) Patients with severe liver damage (up to 3 times normal upper limit of AST and ALT within 28 days before registration) (2) Patients with severe congestive heart failure and acute heart failure (3) Patients taking steroids (4) Patients with a history of diabetic ketoacidosis or diabetic coma during the past 6 months (5) Cancer patients currently undergoing treatment (6) Patients with severe infections, before and after surgery, with severe trauma (7) Patients who are contraindicated or allergic to the test drug (8) Pregnant, possibly pregnant, or wishing to become pregnant during the treatment period and lactating patients (9) Patients who participated in clinical trials or clinical trials of drugs or medical devices at the same time as this study or within 30 days before enrollment in this study (10) Other patients who are judged to be unsuitable as subjects by the judgment of a doctor
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Difference from baseline in DTSQ 6 months after test start
- Secondary Outcome Measures
Name Time Method Body weight, blood pressure, pulse rate, liver function (AST, ALT, gamma GTP), renal function (BUN, Cr, eGFR), uric acid, urinary microalbumin, HbA1c, fasting blood glucose, C-peptide level, diabetic retinopathy, etc. Complications Symptoms, adverse events (nausea, vomiting, etc.)